B
Berra Yazar-Klosinski
CEO of Yazar Lab, Former CSO at Lykos Therapeutics
Key Impact
Pivotal in leading Phase 3 clinical trials for MDMA-assisted therapy for PTSD.
Background & Research
Dr. Berra Yazar-Klosinski is a leading scientist in the regulatory advancement of psychedelic therapies. During her tenure at MAPS and Lykos Therapeutics, she oversaw the design and execution of successful Phase 3 trials for MDMA, demonstrating its efficacy and safety. Her work focuses on clinical development, biomarker research, and establishing rigorous standards for the psychedelic pharmaceutical industry.
Focus Areas
Clinical TrialsMDMARegulatory ScienceToxicology